Comprehensive analysis of bulk and single-cell RNA sequencing data reveals Schlafen-5 (SLFN5) as a novel prognosis and immunity
Yueh-Jung Wu,Chung-Chieh Chiao,Po-Kai Chuang,Chung-Bao Hsieh,Chou-Yuan Ko,Ching-Chung Ko,Chuan-Fa Chang,Tung-Yuan Chen,Ngoc Uyen Nhi Nguyen,Ching-Cheng Hsu,Tian-Huei Chu,Cheng-Chieh Fang,Hsuan-Yen Tsai,Hsien-Chun Tsai,Gangga Anuraga,Hoang Dang Khoa Ta,Do Thi Minh Xuan,Sachin Kumar,Sanskriti Dey,Fitria Sari Wulandari,Rosario Trijuliamos Manalu,Ngoc Phung Ly,Chih-Yang Wang,Yung-Kuo Lee
DOI: https://doi.org/10.7150/ijms.97975
2024-09-09
Abstract:Recent advancements have elucidated the multifaceted roles of the Schlafen (SLFN) family, including SLFN5, SLFN11, SLFN12, SLFN13, and SLFN14, which are implicated in immunological responses. However, little is known about the roles of this gene family in relation to malignancy development. The current study aimed to explore the diagnostic and prognostic potential of Schlafen family genes in colorectal adenocarcinoma (COAD) through bioinformatics analysis. Leveraging advanced bioinformatics tools of bulk RNA-sequencing and single-cell sequencing, we conducted in-depth analyses of gene expressions, functional enrichment, and survival patterns of patients with colorectal cancer compared to normal tissue. Among Schlafen family genes, the transcription levels of SLFN5 in COAD tissues were significantly elevated and correlated with poor survival outcomes. Furthermore, SLFN5 regulated the immune response via Janus kinase (JAK)/signal transduction and activator of transcription (STAT)/interferon (IFN)-alpha/beta signaling. These chemokines in inflammation are associated with diabetes and metabolism, suggesting their involvement in altered cellular energetics for COAD progress. In addition, an immune cell deconvolution analysis indicated a correlation between SLFN5 expression and immune-related cell populations, such as regulatory T cells (Tregs). These findings highlighted the potential clinical significance of SLFN5 in COAD and provided insights into its involvement in the tumor microenvironment and immune regulation. Meanwhile, the drug discovery data of SFLN5 with potential targeted small molecules suggested its therapeutic potential for COAD. Collectively, the current research demonstrated that SFLN5 play crucial roles in tumor development and serve as a prospective biomarker for COAD.